Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

Table 3 SNSB-D scores at baseline and the 24th week

Variables	KGT group (n = 16)			Placebo group (n = 14)			Between-group comparison
Variables	Baseline	24th week	p-value^†	Baseline	24th week	p-value^†	p-value^*
Total SNSB-D score	176.00 (24.76)	198.47 (31.29)	< 0.001	173.79 (32.86)	182.14 (44.25)	0.143	0.249
Attention	10.0 (8.0–11.0)	11.0 (7.3–12.0)	0.285	9.5 (8.0–10.3)	10.0 (7.8–11.0)	0.418	0.541
Language and related function	23.5 (22.3–25.0)	24.5 (22.0–26.0)	0.510	23.0 (20.0–24.3)	23.5 (21.8–25.0)	0.510	0.264
Visuospatial function	34.00 (30.25–35.00)	34.00 (32.25–35.00)	0.304	34.50 (31.75–35.00)	33.50 (32.00–35.00)	1.000	0.622
Memory	57.88 (17.76)	74.34 (22.66)	< 0.001	57.39 (17.97)	66.25 (28.94)	0.051	0.398
Frontal/executive function	52.1 (9.2)	56.4 (8.4)	0.127	51.8 (12.8)	50.4 (12.3)	0.462	0.125

SNSB-D, Seoul Neuropsychological Screening Battery for dementia; KGT, Kami-guibi-tang
Values are presented as means (standard deviations) or medians (Q1–Q3)
^†p-value for the intergroup comparison using the paired t-test or Wilcoxon’s signed rank test
^*p-value for the between-group comparison of the 24th-week scores using the independent t-test or Mann-Whitney U test

ISSN: 2662-7671